{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-027837","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2026-06-09T11:00:23+00:00","discovered_at":"2026-06-09T11:05:00.236411+00:00","generated_at":"2026-06-09T11:06:40.850221+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cocrystal Pharma appoints James Sapirstein as CEO, replacing co-CEOs Lee and Martin","bullets":["James Sapirstein appointed CEO effective June 3, 2026; prior CEO of Entero Therapeutics (Nasdaq: ENTO).","Sam Lee remains President and Chief Scientific Officer; James Martin remains CFO.","Sapirstein receives $265,000 base salary, 50% target bonus, and initial option grant of 235,000 shares at $1.05 vesting over 4 years.","Additional 235,000 options may be granted on 6-month anniversary subject to performance and board approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-027837","json":"https://secwatch.observer/filing/0001493152-26-027837.json","markdown":"https://secwatch.observer/filing/0001493152-26-027837.md","text":"https://secwatch.observer/filing/0001493152-26-027837.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226027837/0001493152-26-027837-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226027837/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T11:06:40.850221+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"08a578973c","claim":"James Martin departed as Co-Chief Executive Officer at Cocrystal Pharma, Inc..","evidence_excerpt":"Mr. Sapirstein replaces Sam Lee and James Martin, who served as the Company’s Co-Chief Executive Officers.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226027837/0001493152-26-027837-index.htm","confidence":0.93,"family_label":"Executive change","details":[{"label":"Action","value":"replaced"},{"label":"Role","value":"Co-Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"6bc2b85435","claim":"Sam Lee departed as Co-Chief Executive Officer at Cocrystal Pharma, Inc..","evidence_excerpt":"Mr. Sapirstein replaces Sam Lee and James Martin, who served as the Company’s Co-Chief Executive Officers.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226027837/0001493152-26-027837-index.htm","confidence":0.93,"family_label":"Executive change","details":[{"label":"Action","value":"replaced"},{"label":"Role","value":"Co-Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"8e5c151f93","claim":"James Sapirstein was appointed as Chief Executive Officer at Cocrystal Pharma, Inc..","evidence_excerpt":"the Board of Directors (the “Board”) of Cocrystal Pharma, Inc. (the “Company”) appointed James Sapirstein as the Chief Executive Officer of the Company, effective immediately","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226027837/0001493152-26-027837-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}